CN113456741A - Composition for preventing hyperuricemia and preparation method thereof - Google Patents
Composition for preventing hyperuricemia and preparation method thereof Download PDFInfo
- Publication number
- CN113456741A CN113456741A CN202110823801.8A CN202110823801A CN113456741A CN 113456741 A CN113456741 A CN 113456741A CN 202110823801 A CN202110823801 A CN 202110823801A CN 113456741 A CN113456741 A CN 113456741A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- composition
- seed powder
- preventing hyperuricemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 179
- 239000007921 spray Substances 0.000 claims abstract description 27
- 238000002156 mixing Methods 0.000 claims abstract description 26
- 229940087559 grape seed Drugs 0.000 claims abstract description 24
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 23
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 23
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 23
- 244000197580 Poria cocos Species 0.000 claims abstract description 23
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 23
- 239000001387 apium graveolens Substances 0.000 claims abstract description 23
- 229920001202 Inulin Polymers 0.000 claims abstract description 22
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 22
- 229940029339 inulin Drugs 0.000 claims abstract description 22
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 18
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 18
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 15
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 13
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 13
- 244000134552 Plantago ovata Species 0.000 claims abstract description 11
- 235000003421 Plantago ovata Nutrition 0.000 claims abstract description 11
- 238000005507 spraying Methods 0.000 claims abstract description 9
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 3
- 238000000265 homogenisation Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 238000000889 atomisation Methods 0.000 claims description 8
- 241000219780 Pueraria Species 0.000 claims description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 29
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 26
- 229940116269 uric acid Drugs 0.000 description 26
- 239000000306 component Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 241001127637 Plantago Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 description 1
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UFCLZKMFXSILNL-PSEXTPKNSA-N Isochlorogenic acid b Chemical compound O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for preventing hyperuricemia and a preparation method thereof, belonging to the technical field of functional foods. The composition comprises the following components in parts by weight: 40-60 parts of grape seed powder, 10-30 parts of plantain seed powder, 10-20 parts of celery seed powder, 14-18 parts of inulin, 6-9 parts of poria cocos powder, 10-15 parts of pseudo-ginseng powder, 9-11 parts of kudzu root powder, 5-8 parts of yam powder and 2-6 parts of honeysuckle powder. The preparation method of the composition comprises the following steps: s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the mixture ratio to obtain a first solution; s2, spraying the first solution in a spray dryer to obtain a mixture; s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain the composition. The composition can effectively prevent hyperuricemia, and has high safety and no side effect.
Description
Technical Field
The invention relates to the technical field of functional foods, in particular to a composition for preventing hyperuricemia and a preparation method thereof.
Background
Since the 21 st century, the social and economic level of China is continuously improved, and the diet is diversified. As fat and high purine food intake increases, the incidence of hyperascorbate (gout) continues to rise. The global hyperuricemia prevalence rate is 5% -25%. Is another common metabolic disease following diabetes. Although China lacks authoritative large-scale epidemiological survey data, according to research and report of the prevalence rate of hyperuricemia in various parts of China in recent years, the number of hyperuricemia patients in the continental region is estimated to reach 2 hundred million at present, middle-aged and elderly men and postmenopausal women are the population, and the incidence of hyperuricemia is remarkably aggravated in recent years, and the prevention and control situation is severe.
Hyperuricemia means that the concentration of urate in blood in a fasting state is higher than a normal saturation value (two detection results on different days), and is divided into two cases of symptom and no symptom. Most individuals with hyperuricemia do not have the associated conditions such as gout, and this phenomenon of high uric acid concentration alone is referred to as asymptomatic hyperuricemia. Asymptomatic hyperuricemia can greatly increase the prevalence of other metabolic diseases, while symptomatic hyperuricemia is often associated with a variety of diseases, particularly gout. Only a small percentage of hyperuricemia will progress to gout, and gout patients must experience a hyperuricemia phase. Physical test criteria for the diagnosis of hyperuricemia are concentrations of urate in the blood of women > 6.0mg/dL (> 360mol/L), men > 7.0mg/dL (> 415mol/L), and children and adolescents > 5.5mg/dL (> 330 mol/L).
Uric acid is the end product of purine metabolism in humans, and most of it (> 70%) is excreted via the kidney. Once uric acid concentrations are outside of physiological ranges, various pathological reactions, such as oxidative stress, apoptosis and inflammation, are initiated. In human blood, the concentration of saturated urate is about 400 μmol/L, so theoretically, it can be presumed that when the concentration of urate exceeds 415 μmol/L, crystals are precipitated and accumulated on blood vessel walls, renal tubules, articular surfaces and other parts, thereby directly or indirectly causing a series of related diseases such as metabolic syndrome, endothelial dysfunction, renal dysfunction, nephropathy, diabetes and the like.
At present, the clinical commonly used uric acid lowering drugs are mainly divided into three categories of drugs for inhibiting uric acid generation, promoting uric acid excretion and promoting uric acid dissolution, which have obvious toxic adverse reactions, such as headache, rash, edema, gastrointestinal bleeding, chronic renal papillary necrosis and lethal hypersensitivity syndrome, and the clinical application of the drugs is limited to a great extent. Traditional Chinese medicine lacks relatively deep mechanism research in the aspect of treating hyperuricemia and has slow effect.
In view of the above, there is an urgent need for innovative and efficient methods for preventing and treating hyperuricemia, which are safe, have no side effects, reduce the incidence of stroke, improve the treatment effect, and treat both symptoms and root causes.
Disclosure of Invention
The invention aims to overcome the technical defects, provides a composition for preventing hyperuricemia and a preparation method thereof, and solves the technical problems of how to efficiently prevent the hyperuricemia and ensure safety and no side effect in the prior art.
In order to achieve the technical purpose, the technical scheme of the invention provides a composition for preventing hyperuricemia and a preparation method thereof.
The invention provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 40-60 parts of grape seed powder, 10-30 parts of plantain seed powder, 10-20 parts of celery seed powder, 14-18 parts of inulin, 6-9 parts of poria cocos powder, 10-15 parts of pseudo-ginseng powder, 9-11 parts of kudzu root powder, 5-8 parts of yam powder and 2-6 parts of honeysuckle powder.
Further, the coating comprises the following components in parts by weight: 60 parts of grape seed powder, 15 parts of plantain seed powder, 10 parts of celery seed powder, 15 parts of inulin, 8 parts of poria cocos powder, 12 parts of pseudo-ginseng powder, 10 parts of pueraria powder, 6 parts of yam powder and 4 parts of honeysuckle powder.
In addition, the invention also provides a preparation method of the composition for preventing hyperuricemia, which comprises the following steps:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the mixture ratio to obtain a first solution;
s2, spraying the first solution in a spray dryer to obtain a mixture;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain the composition.
Further, in step S1, the temperature of the water is 80 ℃ or higher.
Further, before step S2, the method further includes: and homogenizing the first solution by a homogenizer.
Further, the first solution is subjected to two-stage homogenization treatment by a homogenizer, and the sequential pressure of the two-stage homogenization treatment is 20-25MPa and 15-18MPa respectively.
Further, in step S2, the inlet air temperature of the spray dryer is 190 ℃ and the outlet air temperature is 110 ℃ respectively.
Further, in step S2, the atomization frequency of the spray dryer is 250-260 Hz; the feed rate was 18-25 rpm.
Further, in step S3, the mixing speed is 30-40 rpm.
Further, in step S3, the mixing time is 30-40 min.
Compared with the prior art, the invention has the beneficial effects that: the grape seed powder can inhibit the functional disorder of skin cells induced by high uric acid by inhibiting the oxidative stress level, the plantain seed powder is beneficial to discharging uric acid in vivo out of body along with urine, the celery seed powder can improve the activities of superoxide dismutase and glutathione peroxidase in serum, and the inulin can improve the quantity and structure of intestinal flora so as to reduce the level of blood uric acid and inhibit the activity of xanthine oxidase and reduce the level of active oxygen; the poria cocos has the effects of diuresis, bacteriostasis, antibiosis, gout resistance, liver injury protection, immunosuppression and the like, the pseudo-ginseng powder achieves the effect of reducing uric acid by inhibiting the activities of xanthine oxidase and xanthine dehydrogenase, the radix puerariae can inhibit the generation of uric acid, the Chinese yam has the effect of inhibiting the activity of xanthine oxidase in vitro and can reduce the level of uric acid in vivo, 4 compounds of isochlorogenic acid B, isochlorogenic acid A, chlorogenic acid and aesculin in honeysuckle flower have obvious inhibitory activity on the combination of xanthine oxidase, and the remarkable effect of reducing uric acid is achieved; under the comprehensive action of each component and specific dosage, the hyperuricemia can be efficiently prevented, meanwhile, each selected component is a medicine-food component, the safety and the side effect are avoided, the uric acid value is obviously reduced through the intervention of one course of treatment, and the content of the uric acid can be reduced by 45 mu mol/L.
Detailed Description
The specific embodiment provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 40-60 parts of grape seed powder, 10-30 parts of plantain seed powder, 10-20 parts of celery seed powder, 14-18 parts of inulin, 6-9 parts of poria cocos powder, 10-15 parts of pseudo-ginseng powder, 9-11 parts of kudzu root powder, 5-8 parts of yam powder and 2-6 parts of honeysuckle powder.
Further, in certain preferred embodiments, the composition for preventing hyperuricemia comprises the following components in parts by weight: 60 parts of grape seed powder, 15 parts of plantain seed powder, 10 parts of celery seed powder, 15 parts of inulin, 8 parts of tuckahoe powder, 12 parts of pseudo-ginseng powder, 10 parts of kudzuvine root, 6 parts of Chinese yam and 4 parts of honeysuckle powder.
The present embodiment also includes a method for preparing a composition for preventing hyperuricemia, comprising the steps of:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the mixture ratio to dissolve to obtain a first solution, and further carrying out two-stage homogenization treatment on the first solution by a homogenizer, wherein the sequential pressure of the two-stage homogenization treatment is 20-25MPa and 15-18MPa respectively; wherein the temperature of the water is above 80 ℃;
s2, spraying the first solution in a spray dryer to obtain a mixture; the air inlet temperature of the spray dryer is 180-190 ℃, and the air outlet temperature is 100-110 ℃; the atomization frequency of the spray dryer is 250-260 Hz; the feeding speed is 18-25 rpm; the homogenizing spray drying has the advantages that large particles are homogenized into small particles through high-pressure homogenization, so that the product is more favorably and uniformly mixed, and the stability of the product is improved;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder through a three-dimensional mixer to obtain a composition, performing ultraviolet sterilization on the composition, and subpackaging the composition into bags, preferably 10 g/bag, wherein the mixing speed is 30-40 r/min, and the mixing time is 30-40 min. When in use, a bag of the product is taken and is completely dissolved in warm water of about 200ml for direct drinking.
The homogeneous spray drying has the advantages that large particles are homogenized into small particles through high-pressure homogenization, so that the product is more favorably and uniformly mixed, and the stability of the product is improved.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The sources of the raw materials in the following examples or comparative examples are: grape seed powder is purchased from Shaanxi Yunson Biotech limited, lot number: 20200721, respectively; plantago ovata powder is purchased from Shanxi New Tian territory Biotech Co., Ltd, and the batch number is: 20201125003, respectively; celery seed powder is purchased from Fengning safety high-tech practical company Limited, and the batch number is as follows: 201911314102, respectively; tuckahoe powder was purchased from sanyuan tianyu biologicals limited, lot No.: 20200217, respectively; pseudo-ginseng powder is purchased from Shanxi New Tian territory Biotechnology Co., Ltd, batch number: 20201011002, respectively; pueraria powder was purchased from Huaiqingtang pharmaceutical Co., Ltd, Bozhou city, lot number: 20210523, respectively; yam flour was purchased from west anmu fruit biotechnology limited, lot number: MG 21042204; honeysuckle powder was purchased from Guangzhou Huijian Biotechnology Inc., lot number: 20181016-15. In other embodiments the above materials may also be prepared by methods known in the art.
Example 1
The embodiment provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 60 parts of grape seed powder, 15 parts of plantain seed powder, 10 parts of celery seed powder, 15 parts of inulin, 8 parts of poria cocos powder, 12 parts of pseudo-ginseng powder, 10 parts of pueraria powder, 6 parts of yam powder and 4 parts of honeysuckle powder.
The present embodiment also includes a method for preparing the composition for preventing hyperuricemia, comprising the following steps:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the proportion of the components to be dissolved to obtain a first solution, and further carrying out two-stage homogenization treatment on the first solution by a homogenizer, wherein the sequential pressure of the two-stage homogenization treatment is 20MPa and 18MPa respectively; wherein the temperature of the water is 80 ℃;
s2, spraying the first solution in a spray dryer to obtain a mixture; the air inlet temperature of the spray dryer is 180 ℃, and the air outlet temperature of the spray dryer is 110 ℃; the atomization frequency of the spray dryer is 250 Hz; the feed rate was 18 rpm;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain a composition, performing ultraviolet sterilization on the composition, and subpackaging into bags, preferably 10 g/bag, wherein the mixing speed is 30 r/min, and the mixing time is 30 min.
Example 2
The embodiment provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 50 parts of grape seed powder, 20 parts of plantain seed powder, 15 parts of celery seed powder, 14 parts of inulin, 6 parts of tuckahoe powder, 10 parts of pseudo-ginseng powder, 9 parts of kudzu root powder, 5 parts of yam powder and 2 parts of honeysuckle powder.
The present embodiment also includes a method for preparing the composition for preventing hyperuricemia, comprising the following steps:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the mixture ratio to dissolve to obtain a first solution, and further carrying out two-stage homogenization treatment on the first solution by a homogenizer, wherein the sequential pressure of the two-stage homogenization treatment is 25MPa and 15MPa respectively; wherein the temperature of the water is 90 ℃;
s2, spraying the first solution in a spray dryer to obtain a mixture; the air inlet temperature of the spray dryer is 185 ℃, and the air outlet temperature of the spray dryer is 115 ℃; the atomization frequency of the spray dryer is 260 Hz; the feed rate was 20 rpm;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain a composition, performing ultraviolet sterilization on the composition, and subpackaging into bags, preferably 10 g/bag, wherein the mixing speed is 40 r/min, and the mixing time is 35 min.
Example 3
The embodiment provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 40 parts of grape seed powder, 25 parts of plantain seed powder, 20 parts of celery seed powder, 16 parts of inulin, 7 parts of tuckahoe powder, 15 parts of pseudo-ginseng powder, 11 parts of kudzuvine root powder, 7 parts of yam powder and 6 parts of honeysuckle powder.
The present embodiment also includes a method for preparing the composition for preventing hyperuricemia, comprising the following steps:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the proportion of the components to be dissolved to obtain a first solution, and further carrying out two-stage homogenization treatment on the first solution by a homogenizer, wherein the sequential pressure of the two-stage homogenization treatment is 20MPa and 15MPa respectively; wherein the temperature of the water is 85 ℃;
s2, spraying the first solution in a spray dryer to obtain a mixture; the air inlet temperature of the spray dryer is 190 ℃, and the air outlet temperature is 100 ℃; the atomization frequency of the spray dryer is 255 Hz; the feed rate was 25 rpm;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain a composition, performing ultraviolet sterilization on the composition, and subpackaging the composition into bags, preferably 10 g/bag, wherein the mixing speed is 35 r/min, and the mixing time is 35 min.
Example 4
The embodiment provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 45 parts of grape seed powder, 30 parts of plantain seed powder, 10 parts of celery seed powder, 17 parts of inulin, 9 parts of tuckahoe powder, 13 parts of pseudo-ginseng powder, 10 parts of kudzu root powder, 8 parts of yam powder and 5 parts of honeysuckle powder.
The present embodiment also includes a method for preparing the composition for preventing hyperuricemia, comprising the following steps:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the proportion of the components to be dissolved to obtain a first solution, and further carrying out two-stage homogenization treatment on the first solution by a homogenizer, wherein the sequential pressure of the two-stage homogenization treatment is 20MPa and 16MPa respectively; wherein the temperature of the water is 95 ℃;
s2, spraying the first solution in a spray dryer to obtain a mixture; the air inlet temperature of the spray dryer is 180 ℃, and the air outlet temperature is 105 ℃; the atomization frequency of the spray dryer is 250 Hz; the feed rate was 20 rpm;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain a composition, performing ultraviolet sterilization on the composition, and subpackaging into bags, preferably 10 g/bag, wherein the mixing speed is 40 r/min, and the mixing time is 40 min.
Example 5
The embodiment provides a composition for preventing hyperuricemia, which comprises the following components in parts by weight: 55 parts of grape seed powder, 10 parts of plantain seed powder, 20 parts of celery seed powder, 18 parts of inulin, 8 parts of tuckahoe powder, 11 parts of pseudo-ginseng powder, 10 parts of kudzu root powder, 6 parts of yam powder and 3 parts of honeysuckle powder.
The present embodiment also includes a method for preparing the composition for preventing hyperuricemia, comprising the following steps:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the mixture ratio to dissolve to obtain a first solution, and further carrying out two-stage homogenization treatment on the first solution by a homogenizer, wherein the sequential pressure of the two-stage homogenization treatment is 20-25MPa and 15-18MPa respectively; wherein the temperature of the water is above 80 ℃;
s2, spraying the first solution in a spray dryer to obtain a mixture; the air inlet temperature of the spray dryer is 180-190 ℃, and the air outlet temperature is 100-110 ℃; the atomization frequency of the spray dryer is 250 Hz; the feed rate was 18 rpm;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain a composition, performing ultraviolet sterilization on the composition, and subpackaging into bags, preferably 10 g/bag, wherein the mixing speed is 30-40 r/min, and the mixing time is 30-40 min.
Comparative example 1
The composition provided by the comparative example is different from the composition provided by the example 1 in that the part of the grape seed powder is 20 parts, and other components, the using amount and the preparation method are the same as those of the composition provided by the example 1.
Comparative example 2
The composition proposed in this comparative example differs from example 1 in that psyllium powder is not contained, and the other components, amounts, and preparation methods are the same as those of example 1.
Comparative example 3
The comparative example is different from example 1 in that the preparation method is different from example 1, specifically, the comparative example is a composition obtained by directly mixing all the components,
and (4) related tests:
the compositions of examples 1-5 were used to intervene in 160 female patients with hyperuricemia (normal uric acid level range: 155-357u mol/L in female patients), and none of them had complications. The patients with the shortest disease time are 3 months, the patients with the longest disease time are 2 years, and the disease time of 36 patients is between 6 months and 1 year. The 7 days are a treatment course, 20 g/day, 1 bag is respectively eaten half an hour before lunch and dinner, and the food is eaten after being uniformly mixed with boiled water. The judgment standard of the curative effect is as follows: the therapeutic effect is mainly determined by the uric acid level, and the intervention results are shown in Table 1.
TABLE 1 improvement of uric acid values after one treatment course
As can be seen from Table 1, the composition of example 5 showed the most significant effect of reducing uric acid, and in addition, the patient having 387 uric acid levels in the patient of example 5 showed the final uric acid level reduced to 342, which was 45 in total, and further, the comparative examples 1 to 3 showed no significant effect of improving uric acid levels.
In addition, the long-term intervention observation was continued for five 20 patients who had the best intervention, and the results are shown in table 2 below.
TABLE 2 improvement of uric acid levels after one to four treatment courses
As can be seen from Table 2, after four courses of intervention, uric acid levels had stabilized, symptoms had disappeared and returned to healthy levels, and uric acid levels were reduced by 41. mu. mol/L on average.
Compared with the prior art, the raw and auxiliary materials of the product are mainly derived from new resource food or dual-purpose food of medicine and food, and are safe, controllable and free of side effect. And the product is upgraded on the process, so that the stability of the product is improved, and the effect is relatively improved.
The above-described embodiments of the present invention should not be construed as limiting the scope of the present invention. Any other corresponding changes and modifications made according to the technical idea of the present invention should be included in the protection scope of the claims of the present invention.
Claims (10)
1. The composition for preventing hyperuricemia is characterized by comprising the following components in parts by weight: 40-60 parts of grape seed powder, 10-30 parts of plantain seed powder, 10-20 parts of celery seed powder, 14-18 parts of inulin, 6-9 parts of poria cocos powder, 10-15 parts of pseudo-ginseng powder, 9-11 parts of kudzu root powder, 5-8 parts of yam powder and 2-6 parts of honeysuckle powder.
2. The composition for preventing hyperuricemia according to claim 1, comprising the following components in parts by weight: 60 parts of grape seed powder, 15 parts of plantain seed powder, 10 parts of celery seed powder, 15 parts of inulin, 8 parts of poria cocos powder, 12 parts of pseudo-ginseng powder, 10 parts of pueraria powder, 6 parts of yam powder and 4 parts of honeysuckle powder.
3. A method for preparing a composition for preventing hyperuricemia according to any one of claims 1 to 2, comprising the steps of:
s1, adding the Plantago ovata seed powder, the celery seed powder, the tuckahoe powder, the pseudo-ginseng powder, the yam powder and the kudzu root powder into water according to the mixture ratio to obtain a first solution;
s2, spraying the first solution in a spray dryer to obtain a mixture;
s3, mixing the mixture with inulin, grape seed powder and honeysuckle powder to obtain the composition.
4. The method for preparing a composition for preventing hyperuricemia according to claim 3, wherein the temperature of the water is 80 ℃ or higher in step S1.
5. The method for preparing a composition for preventing hyperuricemia according to claim 3, further comprising, before step S2: and homogenizing the first solution by a homogenizer.
6. The method of preparing a composition for preventing hyperuricemia according to claim 5, wherein the first solution is subjected to two-stage homogenization treatment by a homogenizer, and the sequential pressures of the two-stage homogenization treatment are 20-25MPa and 15-18MPa, respectively.
7. The method as claimed in claim 5, wherein in step S2, the inlet air temperature of the spray dryer is 190 ℃ and the outlet air temperature is 110 ℃ respectively.
8. The method for preparing a composition for preventing hyperuricemia according to claim 5, wherein in step S2, the atomization frequency of the spray dryer is 250-260 Hz; the feed rate was 18-25 rpm.
9. The method of preparing a composition for preventing hyperuricemia according to claim 5, wherein the mixing speed is 30 to 40 rpm in step S3.
10. The method for preparing a composition for preventing hyperuricemia according to claim 9, wherein the mixing is performed for 30 to 40min in step S3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110823801.8A CN113456741A (en) | 2021-07-21 | 2021-07-21 | Composition for preventing hyperuricemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110823801.8A CN113456741A (en) | 2021-07-21 | 2021-07-21 | Composition for preventing hyperuricemia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113456741A true CN113456741A (en) | 2021-10-01 |
Family
ID=77881429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110823801.8A Pending CN113456741A (en) | 2021-07-21 | 2021-07-21 | Composition for preventing hyperuricemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113456741A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114947033A (en) * | 2022-05-24 | 2022-08-30 | 武汉英纽林生物科技有限公司 | Prebiotics solid beverage for promoting in vivo hydrogen generation and preparation method thereof |
| CN115177634A (en) * | 2022-07-26 | 2022-10-14 | 武汉英纽林生物科技有限公司 | Anti-gout composition and preparation method and application thereof |
| WO2023190518A1 (en) * | 2022-03-30 | 2023-10-05 | 国立研究開発法人産業技術総合研究所 | Oxidative stress inhibitor, oxidative stress inhibitory composition, and oxidative stress inhibitory device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105727081A (en) * | 2016-04-26 | 2016-07-06 | 广州正广生物科技有限公司 | Healthcare product composition for treating gout |
| CN109329930A (en) * | 2018-11-02 | 2019-02-15 | 广州市臻善科技有限公司 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
| CN112120215A (en) * | 2019-06-24 | 2020-12-25 | 天赋能(天津)健康产业股份有限公司 | Diet suitable for gout and hyperuricemia people |
-
2021
- 2021-07-21 CN CN202110823801.8A patent/CN113456741A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105727081A (en) * | 2016-04-26 | 2016-07-06 | 广州正广生物科技有限公司 | Healthcare product composition for treating gout |
| CN109329930A (en) * | 2018-11-02 | 2019-02-15 | 广州市臻善科技有限公司 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
| CN112120215A (en) * | 2019-06-24 | 2020-12-25 | 天赋能(天津)健康产业股份有限公司 | Diet suitable for gout and hyperuricemia people |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023190518A1 (en) * | 2022-03-30 | 2023-10-05 | 国立研究開発法人産業技術総合研究所 | Oxidative stress inhibitor, oxidative stress inhibitory composition, and oxidative stress inhibitory device |
| CN114947033A (en) * | 2022-05-24 | 2022-08-30 | 武汉英纽林生物科技有限公司 | Prebiotics solid beverage for promoting in vivo hydrogen generation and preparation method thereof |
| CN115177634A (en) * | 2022-07-26 | 2022-10-14 | 武汉英纽林生物科技有限公司 | Anti-gout composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113456741A (en) | Composition for preventing hyperuricemia and preparation method thereof | |
| CN105126067B (en) | A kind of composition of anti-trioxypurine and application thereof | |
| WO2018184525A1 (en) | Composition comprising plant extract and use thereof | |
| CN102764408B (en) | Dealcoholic preparation | |
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| CN110420293A (en) | The plant composition and plant composition solid particle for treating hyperuricemia and gout | |
| CN1814166A (en) | Pulse-promoting powder injecta and preparing method | |
| WO2021078288A1 (en) | Activated insulin, compound momordica charantia peptide oral medicine for treatment of diabetes, and preparation method | |
| CN109123351A (en) | A kind of special doctor's food and preparation method with hyperglycemia population generation meal regulatory function | |
| CN112494616B (en) | Traditional Chinese medicine composition for inhibiting early development and sexual precocity of children and preparation method and application thereof | |
| CN104687048B (en) | Maca tablet and preparation method thereof | |
| CN100374129C (en) | Framberry leaf extract effective part and its composition and uses | |
| CN102824414A (en) | Medicinal tea used for treating constipation | |
| CN107115307A (en) | A kind of Loratadine tablet and preparation method thereof | |
| CN107156819A (en) | A kind of preparation and preparation method thereof of sobering up with anti-alcoholic liver injury effect | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN107714817B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN111840376A (en) | Composition for treating chronic renal failure and preparation method thereof | |
| CN111407836A (en) | A compound wine with blood pressure lowering, blood lipid reducing, and blood sugar lowering effects, and its preparation method | |
| CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
| CN101711793A (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN111905008A (en) | Compound hypoglycemic product and preparation method thereof | |
| CN109486633A (en) | Health liquor and tablet and preparation method thereof as made from Herba Cistanches and korean pine seed | |
| AU2021104015A4 (en) | Composition of nadh for relieving alcohol and protecting liver and use thereof | |
| CN101032562A (en) | Health care product having functions of conditioning blood pressure and protecting haemal system of heart and brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211001 |